Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes. A 30-week Randomised, Double-blind, Double-dummy, Active-controlled, Parallel-group, Multi-centre and Multi-national Trial
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 28 Nov 2018
At a glance
- Drugs Semaglutide (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SUSTAIN; SUSTAIN - CHINA MRCT
- Sponsors Novo Nordisk
- 21 Nov 2018 Planned End Date changed from 20 May 2019 to 17 Apr 2019.
- 21 Nov 2018 Planned primary completion date changed from 24 Sep 2018 to 12 Mar 2019.
- 31 Aug 2018 Biomarkers information updated